Theratechnologies Inc. (THTX)
Automate Your Wheel Strategy on THTX
With Tiblio's Option Bot, you can configure your own wheel strategy including THTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol THTX
- Rev/Share 1.7961
- Book/Share -0.4957
- PB -4.7209
- Debt/Equity -2.0579
- CurrentRatio 1.0759
- ROIC 1.2428
- MktCap 107593244.0
- FreeCF/Share -0.353
- PFCF -6.175
- PE -31.1507
- Debt/Assets 0.8919
- DivYield 0
- ROE 0.1601
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Theratechnologies Reports on its Annual Meeting of Shareholders
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Read More
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Published: April 18, 2025 by: Seeking Alpha
Sentiment: Negative
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV, faces competition and supply issues, with uncertain prospects for its new formulation and other niche products. Theratechnologies' financials are dire, with only $4.6 million in cash and a high burn rate, necessitating urgent external financing or a strategic transaction.
Read More
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
Published: April 11, 2025 by: Business Wire
Sentiment: Neutral
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. (“Theratechnologies”) (NASDAQ: THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51 to $4.50 per share. The proposal represents a total enterprise value of up to $255 million, comprisin.
Read More
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET.
Read More
Theratechnologies Resumes Distribution of EGRIFTA SV®
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV ® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV ® . The product is ready for immediate shipment to network pharmacies.
Read More
About Theratechnologies Inc. (THTX)
- IPO Date 2009-02-13
- Website https://www.theratech.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Paul Lévesque
- Employees 103